Home > Riviste > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Fascicoli precedenti > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2021 May;180(5) > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2021 May;180(5):227-34

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW   

Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2021 May;180(5):227-34

DOI: 10.23736/S0393-3660.20.04482-4

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Dead Corynebacterium parvum human subcutaneous injection: data about safety

Beniamino PALMIERI 1, 2, Maria VADALÀ 1, 2

1 Second Opinion Medical Network, Modena, Italy; 2 Medico Cura Te Stesso Onlus, Modena, Italy



Corynebacterium parvum (C. parvum) is a Propionibacterium family member, that played a primary role in the immunomodulation protocols of experimental and human cancers. The action mechanism of this bacterium, which is inactivated and injected subcutaneously or intravenously, or into the peritoneal and pleural cavity, is to trigger and amplify the innate individual immunity against any pathogenic agent especially viruses (enclosed corona in the animal model) safely and effectively. In this paper we performed a very accurate and careful review of its adverse effects from the immune-oncological studies published so far, specifically the subcutaneous route of melanoma, skin, oral cancers and some breasts tumors. In terms of administration toxicity (especially fever spikes). It has been always reported to be very safe as to the other cancers (breast, colon, lung, abdomen pleura) treated mainly with intravenous and intracavitary protocols. Good overall tolerance has been confirmed, but no death or anaphylactic reactions. Our survey confirms that the inactivated C. parvum can be safely injected subcutaneously in a single or multiple administration schedule as anti-infectious immune-modulant agent.


KEY WORDS: Toxicity; Immunity, innate; Injections, subcutaneous

inizio pagina